Cognition and NeuroImaging in neuroDegenerative Disorders (CogNID)

  • Research type

    Research Study

  • Full title

    Cognition and NeuroImaging in neuroDegenerative Disorders (CogNID)

  • IRAS ID

    250525

  • Contact name

    Akram A. Hosseini

  • Contact email

    akram.hosseini@nuh.nhs.uk

  • Sponsor organisation

    Nottingham University Hospitals NHS Trust

  • Clinicaltrials.gov Identifier

    Pending, Research database: clinicaltrials.gov

  • Duration of Study in the UK

    2 years, 0 months, 30 days

  • Research summary

    Dementia is a common condition which affects middle aged to elderly individuals who suffer from memory loss and thinking difficulties. There is ongoing research describing methods of diagnosing different types of dementia and the underlying disease processes.
    Current psychological assessment tools to diagnose different types of dementia have certain limitations. A recently validated psychological assessment tool, Birmingham Cognitive Screen (BCoS), in stroke patients with memory problems, has shown promise in extending its usage for other purposes.
    We aim to prove the usefulness of BCoS in dementia by comparing scores from people with different forms of dementia to determine whether the BCoS can be used to differentiate between them. We will also compare individuals’ scores from the BCoS with scores from other established tests. We believe the BCoS will provide a more complete and accurate profile to help make more timely diagnoses and thus relieve patient uncertainty and distress.

    Additionally, we aim to improve our understanding of changes in the damage and abnormal functioning of brain cells, in people affected by dementia. We will use cutting edge brain scanning technology, magnetic resonance imaging (MRI) to measure what goes wrong in different parts of the brain and the way groups of cells are damaged.
    We will link these changes to dementia patients’ symptoms and the underlying damage to the brain cells. Results from this study will help us better understand how dementia symptoms evolve over time and potentially assess the effectiveness of any new treatments for dementia in the future.

  • REC name

    East Midlands - Derby Research Ethics Committee

  • REC reference

    18/EM/0292

  • Date of REC Opinion

    14 Nov 2018

  • REC opinion

    Further Information Favourable Opinion